Edgewise Therapeutics, Inc.
US ˙ NasdaqGS ˙ US28036F1057

SecurityEWTX / Edgewise Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Squarepoint Ops LLC closes position in EWTX / Edgewise Therapeutics, Inc.

On February 13, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 0 shares of Edgewise Therapeutics, Inc. (US:EWTX) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 75,276 shares of Edgewise Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 0 -100.00 0
2025-11-14 2025-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 75,276 75,276 1,221 0.0012
2025-08-27 2025-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 0 -45,756 -100.00 0 -100.00
2025-08-14 2025-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 0 -45,756 0
2025-08-27 2025-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 45,756 19,398 73.59 1,007 43.10 0.0012
2025-05-15 2025-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 45,756 19,398 1,007 0.0012
2025-02-14 2024-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 26,358 9,729 58.51 704 58.69 0.0007
2024-11-14 2024-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 16,629 -35,912 -68.35 444 -53.17 0.0007
2024-08-14 2024-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 52,541 27,687 111.40 946 108.83 0.0016
2024-05-15 2024-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 24,854 13,244 114.07 453 256.69 0.0008
2024-02-14 2023-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 11,610 11,610 127 0.0002
2022-05-16 2022-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 0 -12,197 -100.00 0 -100.00
2022-02-14 2021-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 12,197 12,197 186 0.0005
2021-08-16 2021-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 0 -20,185 -100.00 0 -100.00
2021-05-17 2021-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 20,185 20,185 656 0.0038
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.